Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 223-233

  Mullauer, Franziska B ^a   Van Bloois, Louis ^b   Daalhuisen, Joost B ^a   Ten Brink, Marieke S ^a   Storm, Gert ^b   Medema, Jan Paul ^a   Schiffelers, Raymond M ^b   Kessler, Jan H ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

betulinic acid; colorectal cancer; drug delivery system; formulation; liposomes; lung cancer; mice; xenograft model

Indexed keywords

BETULIC ACID; CHOLESTEROL; LIPOSOME; POVIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; FEMALE; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR GROWTH; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LUNG; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOCHONDRIA; RHODAMINES; TRITERPENES;

EID: 79951679702     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283421035     Document Type: Article

References (60)

1. Kim J, Park EJ. Cytotoxic anticancer candidates from natural resources. Curr Med Chem Anticancer Agents 2002; 2:485-537. (Pubitemid 34649887)
2. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008; 14:1610-1617. (Pubitemid 351469444)
3. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009; 20:880-892.
4. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009; 14:885-890.
5. Mullauer FB, Kessler JH, Medema JP. Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010; 21:215-227.
6. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1:1046-1051.
7. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273:33942-33948. (Pubitemid 29008858)
8. Mullauer FB, Kessler JH, Medema JP. Betulinic acid induces cytochrome C release and apoptosis in a Bax/Bak independent, permeability transition pore dependentfashion. Apoptosis 2009; 14:191-202.
9. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67:2816-2823. (Pubitemid 46548971)
10. Pandey MK, Sung B, Aggarwal BB. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 2010; 127:282-292.
11. Chowdhury A, Mandal S, Mittra B, Sharma S, Mukhopadhyay S, Majumder H. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit 2002; 8:BR254-BR265.
12. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, et al. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57:4956-4964. (Pubitemid 27469008)
13. Schmidt ML, Kuzmanoff KL, Ling-Indeck L, Pezzuto JM. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 1997; 33:2007-2010. (Pubitemid 28123444)
14. Fulda S, Jeremias I, Steiner HH, Pietsch T, Debatin KM. Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 1999; 82:435-441. (Pubitemid 29302986)
15. Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 1999; 289:1306-1312. (Pubitemid 29246659)
16. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002; 175:17-25. (Pubitemid 33153040)
17. Thurnher D,Turhani D, Pelzmann M, Wannemacher B, Knerer B, Formanek M, et al. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 2003; 25:732-740. (Pubitemid 37034260)
18. Ehrhardt H, Fulda S, Fuhrer M, Debatin KM, Jeremias I. Betulinic acid-induced apoptosis in leukemia cells. Leukemia 2004; 18:1406-1412. (Pubitemid 39136751)
19. Kessler JH, Mullauer FB, de Roo GM, Medema JP. Broad in-vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett 2006; 251:132-145. (Pubitemid 46589768)
20. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B, et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 2000; 114:935-940. (Pubitemid 30252714)
21. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC Pharmacological evaluation of C-3-modified betulinic acid derivatives with potent anticancer activity. Invest New Drugs 2008; 26:25-34.
22. Sandberg F, Dutschewska H, Christov V, Spassov S. Spondianthus preussii var. grabber Engler. Pharmacological screening and occurrence of triterpenes. Acta Pharm Suec 1987; 24:253-256.
23. Jeong HJ, Chai HB, Park SY, Kim DS. Preparation of amino acid conjugates of betulinic acid with activity against human melanoma. Bioorg Med Chem Lett 1999; 9:1201-1204. (Pubitemid 29204685)
24. Kim JY, Koo HM, Kim DS. Development of C-20-modified betulinic acid derivatives as antitumoragents. Bioorg Med Chem Lett 2001; 11:2405-2408. (Pubitemid 32781710)
25. Gauthier C, Legault J, Lebrun M, Dufour P, Pichette A. Glycosidation of lupane-type triterpenoids as potent in-vitro cytotoxic agents. Bioorg Med Chem 2006; 14:6713-6725. (Pubitemid 44233310)
26. Drag-Zalesinska M, Kulbacka J, Saczko J, Wysocka T, Zabel M, Surowiak P, et al. Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells. Bioorg Med Chem Lett 2009; 19:4814-4817.
27. Kommera H, Kaluderovic GN, Kalbitz J, Paschke R. Lupane triterpenoids betulin and betulinic acid derivatives induce apoptosis in tumor cells. Invest New Drugs 2009. doi 10.1007/s10637-009-9358-x.
28. Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest 2009; 39:384-394.
29. Csuk R, Barthel A, Schwarz S, Kommera H, Paschke R. Synthesis and biological evaluation of antitumor-active gamma-butyrolactone substituted betulin derivatives. Bioorg Med Chem 2010; 18:2549-2558.
30. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303:1818-1822. (Pubitemid 38374867)
31. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30:592-599.
32. Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target 2006; 14:301-310. (Pubitemid 44173296)
33. Schiffelers RM, Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int J Pharm 2008; 364:258-264.
34. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13:238-252.
35. Rouser G, Fkeischer S, Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5:494-496.
36. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24:148-154. (Pubitemid 19163397)
37. Wu J, Houghton PJ. Interval approach to assessing antitumor activity for tumor xenograft studies. Pharm Stat 2010; 9:46-54.
38. Waller DP, Zaneveld LJ, Fong HH. In-vitro spermicidal activity of gossypol. Contraception 1980; 22:183-187.
39. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-284. (Pubitemid 30122932)
40. Finkelstein MC, Weissmann G. Enzyme replacement via liposomes: variations in lipid compositions determine liposomal integrity in biological fluids. Biochim Biophys Acta 1979; 587:202-216. (Pubitemid 10235872)
41. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980; 186:591-598.
42. Socaciu C, Jessel R, Diehl HA. Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy. Chem Phys Lipids 2000; 106:79-88. (Pubitemid 30394593)
43. Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999; 40:75-87. (Pubitemid 29486605)
44. Schwendener RA, Horber DH, Odermatt B, Schott H. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 1996; 122: 102-108. (Pubitemid 26037055)
45. Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des 2008; 14:1124-1137. (Pubitemid 351982559)
46. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747-1757. (Pubitemid 43767064)
47. Son LB, Kaplun AP, Spilevskii AA, Andiia-Pravdivyi I, Alekseeva SG, Gribor'ev VB, et al. Synthesis of betulinic acid from betulin and study of its solubilization using liposomes. Bioorg Khim 1998; 24:787-793.
48. Castor TP. Phospholipid nanosomes. Curr Drug Deliv 2005; 2:329-340. (Pubitemid 41277765)
49. Cichewicz RH, Kouzi SA. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid forthe prevention and treatment of cancer and HIV infection. Med Res Rev 2004; 24:90-114. (Pubitemid 38018596)
50. Clark AM, Hufford CD. Use of microorganisms for the study of drug metabolism: an update. Med Res Rev 1991; 11:473-501.
51. Venisetty RK, Ciddi V. Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr Pharm Biotechnol 2003; 4:153-167. (Pubitemid 36665400)
52. Kouzi SA, Chatterjee P, Pezzuto JM, Hamann MT. Microbial transformations of the antimelanoma agent betulinic acid. J Nat Prod 2000; 63:1653-1657. (Pubitemid 32038610)
53. Chatterjee P, Kouzi SA, Pezzuto JM, Hamann MT. Biotransformation of the antimelanoma agent betulinic acid by Bacillus megaterium ATCC 13368. Appl Environ Microbiol 2000; 66:3850-3855.
54. Fulda S, Jeremias I, Debatin KM. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004; 23:7611-7620. (Pubitemid 39424919)
55. Sawada N, Kataoka K, Kondo K, Arimochi H, Fujino H, Takahashi Y, et al. Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 2004; 90:1672-1678. (Pubitemid 38648255)
56. Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK, et al. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 2007; 101:277-285. (Pubitemid 350194804)
57. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, Kenzaki K, et al. Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 2009; 125:952-960.
58. Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009; 6:207-218.
59. Talelli M, Rijcken CJ,Van Nostrum CF, Storm G, Hennink WE. Micelles based on HPMA copolymers. Adv Drug Deliv Rev 2010; 62:231-239.
60. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58:173-182. (Pubitemid 38479922)